Optimizing the Benefit of Multiple Sclerosis Therapy: the Importance of Treatment Adherence

Overview

Journal Patient Prefer Adherence

Date 2010 Feb 19

PMID 20165593

Citations 75

Authors

Francesco Patti

Affiliations

Soon will be listed here.

Abstract

Poor treatment adherence is problematic in many therapy areas, including multiple sclerosis (MS). Several immunomodulatory drugs are available for the treatment of MS, all of which require frequent parenteral administration. Current first-line therapies are two formulations of interferon (IFN) beta-1a, one of IFN beta-1b, and one of glatiramer acetate. Discontinuation of treatment is common, particularly in the first few months after initiation. Although the true effect of poor adherence to MS therapy is not known, it is likely to lead to a fall in treatment efficacy. Many factors influence a patient's adherence to treatment, including the patient's MS subtype and disability level, cognitive impairment resulting from MS, perceived lack of efficacy of the prescribed medication, and adverse events associated with MS therapy. This article summarizes the barriers to adherence to MS therapies, and discusses patient management strategies that can be employed to encourage adherence. Future advances in the field of MS treatment will be explored, including the development of orally administered drugs, which may enhance adherence.

Citing Articles

The Efficacy of Fingolimod and Interferons in Controlling Disability and Relapse Rate in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.

Shaygannejad V, Mirmosayyeb O, Bagherieh S, Shaygan P, Ghajarzadeh M Int J Prev Med. 2024; 14:131.

PMID: 38449687 PMC: 10916411. DOI: 10.4103/ijpvm.ijpvm_12_22.

Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.

Feng G, Posa S, Sureshkumar A, Simpson S, Bruno T, Morrow S J Neurol. 2024; 271(3):1084-1107.

PMID: 38219252 DOI: 10.1007/s00415-023-12116-z.

The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity.

Hendin B, Brook R, Beren I, Kleinman N, Fink C, Phillips A J Health Econ Outcomes Res. 2023; 10(1):91-101.

PMID: 37069893 PMC: 10105615. DOI: 10.36469/001c.57593.

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.

Baryakova T, Pogostin B, Langer R, McHugh K Nat Rev Drug Discov. 2023; 22(5):387-409.

PMID: 36973491 PMC: 10041531. DOI: 10.1038/s41573-023-00670-0.

Effects of a nurse-led structured home visiting program on quality of life and adherence to treatment in hemodialysis patients.

Pooresmaeil M, Iranpour S, Aghamohammadi M Front Public Health. 2023; 11:1013019.

PMID: 36969622 PMC: 10034095. DOI: 10.3389/fpubh.2023.1013019.

References

Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L . Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci. 2007; 259(1-2):104-8. DOI: 10.1016/j.jns.2006.05.075. View

Kruk M, Schwalbe N . The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2007; 28(12):1989-95. DOI: 10.1016/j.clinthera.2006.12.011. View

Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C . Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2005; 17(2):205-10. DOI: 10.1093/annonc/mdj044. View

Frohman E, Phillips T, Kokel K, Van Pelt J, OLeary S, Gross S . Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist. 2003; 8(4):227-36. DOI: 10.1097/00127893-200207000-00003. View

Giovannoni G, Barbarash O, Casset-Semanaz F, King J, Metz L, Pardo G . Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2008; 15(2):219-28. DOI: 10.1177/1352458508097299. View

Romine J, Sipe J, Koziol J, Zyroff J, Beutler E . A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999; 111(1):35-44. DOI: 10.1046/j.1525-1381.1999.09115.x. View

Beutler E, Sipe J, Romine J, Koziol J, McMillan R, Zyroff J . The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996; 93(4):1716-20. PMC: 40008. DOI: 10.1073/pnas.93.4.1716. View

Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato M . Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2007; 59(3-4):131-5. DOI: 10.1159/000111875. View

Mohr D, Goodkin D, Likosky W, Gatto N, Baumann K, Rudick R . Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997; 54(5):531-3. DOI: 10.1001/archneur.1997.00550170015009. View

10.

Kappos L, Antel J, Comi G, Montalban X, OConnor P, Polman C . Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355(11):1124-40. DOI: 10.1056/NEJMoa052643. View

11.

Phillips J, Rice G, Frohman E, Vande Gaer L, Scott T, Haas J . A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther. 2004; 26(4):511-21. DOI: 10.1016/s0149-2918(04)90053-7. View

12.

Richter A, Anton S, Anton S, Koch P, Dennett S . The impact of reducing dose frequency on health outcomes. Clin Ther. 2003; 25(8):2307-35. DOI: 10.1016/s0149-2918(03)80222-9. View

13.

Cox D, Stone J . Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006; 38(3):167-71. DOI: 10.1097/01376517-200606000-00005. View

14.

Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo M . Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005; 11(3):306-9. DOI: 10.1191/1352458505ms1173oa. View

15.

Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J . A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005; 11(5):585-91. DOI: 10.1191/1352458505ms1197oa. View

16.

Bayas A, Rieckmann P . Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf. 2000; 22(2):149-59. DOI: 10.2165/00002018-200022020-00006. View

17.

Reginster J, Rabenda V, Neuprez A . Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006; 38(4 Suppl 1):S2-6. DOI: 10.1016/j.bone.2006.01.150. View

18.

Walther E, Hohlfeld R . Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999; 53(8):1622-7. DOI: 10.1212/wnl.53.8.1622. View

19.

Atkinson M, Sinha A, Hass S, Colman S, Kumar R, Brod M . Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2:12. PMC: 398419. DOI: 10.1186/1477-7525-2-12. View

20.

Glanz B, Holland C, Gauthier S, Amunwa E, Liptak Z, Houtchens M . Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler. 2007; 13(8):1004-10. DOI: 10.1177/1352458507077943. View